Schep et al. 2016: Ibogaine for Drug Dependence—“What Is a Safe Dose?” Toxicity Caution

Definition box

Definition: Leo J. Schep, Robin J. Slaughter, Susanna Galea, and David Newcombe (2016) published *Ibogaine for treating drug dependence. What is a safe dose?* in *Drug and Alcohol Dependence* (doi: 10.1016/j.drugalcdep.2016.07.005; PMID 27426011; *Drug Alcohol Depend* 166:1–5). This is a toxicology-focused review/commentary arguing that clinic doses used to produce intense psychoactive effects for dependence treatment sit far above a cautiously extrapolated human starting dose derived from limited animal NOAEL/lethality data and safety factors. Authors highlight case evidence of ataxia, gastrointestinal distress, ventricular arrhythmias, and sudden unexplained deaths, plus rodent cerebellar Purkinje injury themes at pharmacologically active animal doses. Their illustrative calculation yields an approximate initial human dose on the order of 0.87 mg/kg—substantially lower than many reported treatment regimens—and warns that morbidities/mortalities will continue unless practitioners reconsider dosing in susceptible patients. Label review/dose-safety commentary—not an efficacy RCT, not a cure, and not proof of psychoactive IV ibogaine infusion. Ibogaine is U.S. Schedule I and not FDA-approved. QTc/cardiac risk remains central.

Quotable answer (56 words)

Schep and colleagues’ 2016 Drug and Alcohol Dependence paper warns that common ibogaine treatment doses dwarf a cautiously extrapolated ~0.87 mg/kg starting estimate and catalogs ataxia, arrhythmias, and deaths. It is a toxicity dose-safety review—not proof that psychoactive IV ibogaine infusion works. Schedule I; cardiac screening first; no cure claims.

Why this paper-spoke exists

Dose folklore online often treats “mg/kg flood” as tradition rather than toxicology. Schep et al. force a uncomfortable question: what is a safe dose?—and answer that current practice may be misaligned with animal-derived caution. Soft CTA: /safety-and-screening → /apply. Pair with Litjens & Brunt toxicity review (/blog/litjens-brunt-2016-ibogaine-toxicity), AE systematic review (/blog/ona-2022-ibogaine-adverse-events-review), and QTc clinical data (/blog/knuijver-2021-ibogaine-qtc-safety).

What was published

| Feature | Accurate description | |---------|----------------------| | Citation | Schep L.J., Slaughter R.J., Galea S., Newcombe D. Ibogaine for treating drug dependence. What is a safe dose? *Drug Alcohol Depend*. 2016;166:1–5. doi 10.1016/j.drugalcdep.2016.07.005. PMID 27426011 | | Type | Review / dose-safety toxicology commentary | | Focus | Human case toxicities; receptor pharmacology; animal neurotoxicity/lethality; HED/safety-factor logic | | Illustrative cautionary figure | ~0.87 mg/kg approximated initial human dose after safety factors (authors’ framing) | | Clinical harms emphasized | Ataxia, GI distress, ventricular arrhythmias, sudden unexplained deaths | | What it is not | New RCT; FDA label; IV brand efficacy proof; permission to DIY dose |

Methods (plain language)

Authors synthesize published toxicology and treatment-context reports, then apply a classic toxicology translation idea: take limited animal NOAEL/lethality information, convert toward a human equivalent dose, and apply safety factors for species differences and susceptible populations (including people with substance use disorders). The resulting starting-dose estimate is a cautionary toxicology construct, not a validated therapeutic regimen and not a recommendation to self-administer any amount.

Key points (no hype)

• Western adoption of ibogaine for dependence often uses large doses intended to produce intense psychoactive effects as part of the treatment narrative.
• Case reports/series continue to document neurologic, gastrointestinal, and cardiac harms, including deaths.
• High doses act across multiple receptor/transporter classes (sigma-2, opioid, serotonergic, nicotinic, NMDA-related themes as summarized).
• Limited toxicology suggests rodent intraperitoneal doses that alter addiction-related behaviors can also injure cerebellar Purkinje cells.
• Limited oral lethality data in rodents (authors discuss approximate oral LD themes near 263 mg/kg in that literature) still require large safety margins before human starting-dose thinking.
• After safety-factor application, authors approximate an initial human dose around 0.87 mg/kg—far below many clinic flood traditions.
• Bottom-line warning: morbidities and mortalities will continue unless dosing is reconsidered for susceptible patients.

Honest reading: “What is a safe dose?” is partly rhetorical—the paper’s thrust is that common doses may not be safe, not that a consumer product dose has been approved.

Cardiac / YMYL context

Schep’s arrhythmia and sudden-death emphasis maps onto later and parallel cardiac literature:

• hERG blockade mechanism (/blog/alper-herg-ibogaine-cardiac-mechanism)
• Clinical QTc observations (/blog/knuijver-2021-ibogaine-qtc-safety)
• CV complications teaching (/blog/ibogaine-cardiovascular-complications-review)
• Practical ECG/telemetry checklists (/blog/ibogaine-ecg-pre-infusion-checklist, /blog/ibogaine-telemetry-acls-monitoring)

Do not treat any calculated mg/kg figure as DIY instructions. Screening culture beats dose arithmetic (/safety-and-screening).

Route honesty

Schep et al. discuss dependence-treatment dosing traditions that are typically oral (or otherwise non–brand-IV). Their toxicology caution does not become evidence that physician-supervised psychoactive IV ibogaine infusion is proven safe or effective. Support IV ≠ psychoactive IV (/blog/ibogaine-oral-vs-iv). Entity: /what-is-ibogaine-infusion.

Limits and confounders

| Limit | Why it matters | |-------|----------------| | Narrative toxicology synthesis | Not a prospective dose-finding RCT | | Sparse animal NOAEL data | Extrapolation uncertainty is large—authors acknowledge limited toxicology | | 0.87 mg/kg is illustrative caution | Not an FDA-validated therapeutic dose | | Case confounding | Adulterants, unknown purity, polypharmacy, delayed medical care | | 2016 evidence horizon | Co-read newer AE/CV reviews | | Not brand-IV stratified | Cannot validate IV psychoactive marketing |

What this does NOT prove for IV ibogaine infusion brand

| Claim | Status | |-------|--------| | “Authors calculated a safe consumer dose to buy online” | False / dangerous | | “Toxicity paper proves treatment efficacy” | False | | “Lower calculated dose means no cardiac monitoring needed” | Dangerously false | | Cite as 2016 dose-safety warning against high traditional floods? | Yes |

No cure claims. Schedule I / not FDA-approved.

Soft CTA

If dose charts on forums feel more concrete than medical screening, invert that priority. Start at /safety-and-screening, then /apply only if exploring physician-supervised IV ibogaine infusion questions under medical governance. Entity: /what-is-ibogaine-infusion.

FAQ

What is the Schep 2016 paper? A *Drug and Alcohol Dependence* dose-safety/toxicity review: *Ibogaine for treating drug dependence. What is a safe dose?* (doi **10.1016/j.drugalcdep.2016.07.005**).

Did they run a new clinical trial? No—literature synthesis plus toxicology dose-extrapolation caution.

What harms do they emphasize? Ataxia, GI distress, ventricular arrhythmias, and sudden unexplained deaths, among other themes.

What is the ~0.87 mg/kg figure? An authors’ approximated cautious initial human dose after safety factors—not an approved therapy dose and not DIY guidance.

Does this prove IV ibogaine infusion works? No.

Is ibogaine FDA-approved? No. Schedule I; not FDA-approved.

Should cardiac screening still happen at “low” doses? Yes—risk is multifactorial; do not self-calibrate from a review figure alone.

Where should screening start? /safety-and-screening, then /apply if appropriate.

Medical disclaimer

Educational research synopsis only—not medical, psychiatric, or legal advice, and not a guarantee of outcomes. Ibogaine can prolong the QTc interval and has been associated with serious cardiac events including torsades de pointes and death in some contexts. Ibogaine is Schedule I in the United States and is not FDA-approved for any indication. Provisional Mexico programs discussed on this site are not U.S. FDA clinics. Soft CTAs: /safety-and-screening, /apply.

Schep et al. 2016 is a dose-safety toxicity review—not personal access, not a cure claim, not dosing instructions, and not psychoactive IV ibogaine efficacy proof.

Sources (selected)

1. Schep L.J., Slaughter R.J., Galea S., Newcombe D. Ibogaine for treating drug dependence. What is a safe dose? *Drug Alcohol Depend*. 2016;166:1–5. doi: 10.1016/j.drugalcdep.2016.07.005. PMID: 27426011.
2. Litjens R.P.W., Brunt T.M. How toxic is ibogaine? *Clin Toxicol*. 2016;54(4):297–302. doi: 10.3109/15563650.2016.1138226.
3. Alper K. et al. hERG blockade by iboga alkaloids. *Cardiovasc Toxicol*. 2016;16(1):14–22. doi: 10.1007/s12012-015-9311-5.
4. Knuijver T. et al. *Addiction*. 2021. doi: 10.1111/add.15448.
5. 21 CFR 1308.11 — ibogaine Schedule I (United States).